NRG Therapeutics is a neuroscience-focused biotech dedicated to developing disease-modifying treatments for neurodegenerative disorders like Parkinson’s disease and ALS (motor neurone disease). Their approach centers on restoring mitochondrial health by developing brain-penetrant, orally available small molecule inhibitors of the mitochondrial permeability transition pore (mPTP), a regulator implicated in energy failure, inflammation, and neuron death. Their lead candidate, NRG5051, has been selected for development, and they have just completed a successful Series B financing to support advancing clinical data generation in Parkinson’s and proof-of-concept studies in ALS/MND.